Why is Remedium Life falling/rising?

As of 19-Sep, Remedium Lifecare Ltd's stock price is currently at 1.52, reflecting an increase of 0.02 or 1.33%. The stock has shown a performance of 16.03% over the past month, although it has significantly underperformed over the year with a decline of 76.31%. Today's price summary indicates that the stock has outperformed its sector by 1.79%, and it is trading higher than its 5-day, 20-day, 50-day, and 100-day moving averages, although it remains below its 200-day moving average. However, there is a concerning trend with a 27.73% drop in delivery volume compared to the 5-day average, suggesting falling investor participation. Additionally, the company faces significant challenges, including a high Debt to EBITDA ratio of -1.00 times, negative returns on capital employed, and a drastic decline in net sales, which has contributed to its poor long-term growth outlook.
In the broader market context, the stock's short-term performance has been relatively better than the benchmark, as it has gained 16.03% in the last month while the Sensex has only increased by 1.20%. However, the stock's year-to-date performance is concerning, with a decline of 57.47% compared to the Sensex's gain of 5.74%. The overall market has been more stable, with the BSE500 showing a slight negative return of -1.96% over the past year, while Remedium Lifecare's stock has drastically underperformed with a return of -76.31%. This stark contrast highlights the company's ongoing struggles and the risks associated with its financial health, which may deter potential investors despite the recent uptick in price.